Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris

DealWatch_1200x675

Related Content

Perrigo's OTC Core Could Expand To Include National Brands

Aug 10 2018

Akcea Waylivra's Surrogate Endpoint Gains Support At US FDA Advisory Committee

May 11 2018

Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

Jun 01 2018

Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

Aug 01 2018

Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy

Aug 06 2018

Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal

Aug 06 2018

Onward Ho! Glenmark Strikes First Onco Asset Deal With China’s Harbour BioMed

Aug 06 2018

Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs

Aug 07 2018

Related Companies

Allergan plc

Editas Medicine

Regeneron Pharmaceuticals, Inc.

Genetix Biotherapeutics

Perrigo Company PLC

Glenmark Pharmaceuticals Limited

Harbour BioMed

Boehringer Ingelheim GmbH

Roche Holding AG

Pieris Pharmaceuticals, Inc.

Sanofi

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

Les Laboratoires Servier

Seagen Inc.

Sarepta Therapeutics, Inc.

Lacerta Therapeutics, Inc.

The University of Florida Research Foundation

Acadia Pharmaceuticals Inc.

Neuren Pharmaceuticals Limited

Ionis Pharmaceuticals, Inc.

Akcea Therapeutics, Inc.

PTC Therapeutics, Inc.

Endo, Inc.

Nevakar, Inc.

Par Pharmaceutical Companies Inc.

Pfizer Inc.

Pfizer Inc.

Synergy Pharmaceuticals, Inc.

Cipher Pharmaceuticals Inc.

Additional Topics

Deals Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window